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Identiﬁcation of platelet function defects by
multi-parameter assessment of thrombus
formation
Susanne M. de Witt1, Frauke Swieringa1,*, Rachel Cavill2,*, Moniek M.E. Lamers1, Roger van Kruchten1,
Tom Mastenbroek1, Constance Baaten1, Susan Coort3, Nicholas Pugh4, Ansgar Schulz5, Inge Scharrer6,
Kerstin Jurk6, Barbara Zieger7, Kenneth J. Clemetson8, Richard W. Farndale9, Johan W.M. Heemskerk1,*
& Judith M.E.M. Cosemans1,*
Assays measuring platelet aggregation (thrombus formation) at arterial shear rate mostly use
collagen as only platelet-adhesive surface. Here we report a multi-surface and multi-para-
meter ﬂow assay to characterize thrombus formation in whole blood from healthy subjects
and patients with platelet function deﬁciencies. A systematic comparison is made of
52 adhesive surfaces with components activating the main platelet-adhesive receptors,
and of eight output parameters reﬂecting distinct stages of thrombus formation. Three
types of thrombus formation can be identiﬁed with a predicted hierarchy of the following
receptors: glycoprotein (GP)VI, C-type lectin-like receptor-2 (CLEC-2)4GPIb4a6b1,
aIIbb34a2b14CD36, a5b1, avb3. Application with patient blood reveals distinct abnormalities
in thrombus formation in patients with severe combined immune deﬁciency, Glanzmann’s
thrombasthenia, Hermansky–Pudlak syndrome, May–Hegglin anomaly or grey platelet syn-
drome. We suggest this test may be useful for the diagnosis of patients with suspected
bleeding disorders or a pro-thrombotic tendency.
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T
he fundamental role of platelets in haemostasis and
thrombosis relies on their capability of adhesion to speciﬁc
locations of the perturbed vessel wall upon injury, damage
or inﬂammation. Continued adhesion of ﬂowing platelets leads to
buildup of a platelet plug or thrombus and is required to stop
bleeding or, under pathological conditions, to induce thrombosis,
for instance after rupture of an atherosclerotic plaque1. Many
experimental studies with genetically modiﬁed mice or with
blood from patients with haemostatic deﬁciencies, performed at
either arterial (high shear rate) or venous (low shear rate) ﬂow
conditions, have emphasized that thrombus formation is a
complex process encompassing multiple platelet receptors and
signalling mechanisms2–4.
For over two decades, parallel-plate ﬂow chambers have been
used to measure platelet adhesion and activation under arterial or
venous ﬂow conditions, in particular using surfaces such as
extracellular matrix or collagen5,6. Currently, this process of
platelet adhesion and aggregation in ﬂow devices is described as
ﬂow-dependent thrombus formation, regardless of the presence
or absence of anticoagulants4. Whole-blood ﬂow chamber tests
with blood from many strains of genetically modiﬁed mice have
revealed platelet function defects under ﬂow in vitro that often
associate with a reduced arterial thrombosis tendency in vivo1,7,8.
These outcomes have boosted the use of commercial and
home-made ﬂow devices, in particular for the assessment of
human platelet activity in preclinical settings, in spite of the
fact that international recommendations stress the need for
further standardization of devices, protocols and measurement
parameters9. In recent years, various types of microﬂuidic devices
have been developed requiring only small volumes of human
blood10,11, including devices containing endothelium, for instance
to study blood from patients with sickle cell disease12.
Unfortunately, however, the great variation in design and use of
the microﬂuidic chips hinders the process of standardization13.
On the other hand, relatively simple, one-parameter microﬂuidics
tests using collagen surfaces have already been employed to
determine inter-subject variability and the efﬁcacy of antiplatelet
therapy in cardiac patients14–17.
Clinically, the PFA-100 is the only device currently validated
that assesses platelet function under high-shear ﬂow conditions,
by measuring the occlusion time due to platelet aggregation on a
collagen matrix. The PFA-100 is frequently utilized to evaluate
deﬁciencies in platelet function or von Willebrand factor (vWF)
activity, but it only provides a single end-stage parameter.
Current guidelines for laboratory investigations to check for
heritable disorders of platelet function recommend the PFA-100
as an optional screening test, but also stipulate that this test is not
diagnostic and is insensitive to mild platelet disorders18. Taken
together, there are promising possibilities for clinical employment
of ﬂow assays to test platelet adhesion and aggregation, but
current methods often are incompletely developed and
insufﬁciently standardized.
The classic concept of ﬂow-dependent thrombus formation is
based on collagen-dependent models of platelet aggregation, both
in vivo in damaged mouse vessels and in vitro using collagen-
coated ﬂow devices. Fibrillar collagen (collagen I or III) is
considered as the primary platelet-activating substance in the
damaged vessel wall controlling the thrombotic process2,4,8,19,20.
The concept, in brief, is that at high arterial wall shear rate, initial
platelet rolling is regulated by the interaction of platelet
glycoprotein Ib-V-IX (GPIb) to vWF which is bound to
collagen. Platelet adhesion and activation by vWF/collagen then
is enforced by interplay of the collagen receptors, glycoprotein VI
(GPVI) and integrin a2b1, and the ﬁbrinogen receptor, integrin
aIIbb3 (refs 21,22). Platelets may ﬁrst adhere via integrins and
then become activated via GPVI, or ﬁrst interact with GPVI23.
Collagen-induced activation of platelets includes rises in cytosolic
Ca2þ , secretion of dense and a-granules (monitored as P-selectin
expression) and release of autacoids such as ADP, ATP and
thromboxane A2, thus resulting in a plethora of paracrine
substances able of recruiting and capturing other passing
platelets. Together with GPVI, these mediators induce afﬁnity
changes in integrins a2b1 and aIIbb3, which are required for
thrombus stability24,25. Additionally, GPVI signalling stimulates
platelet procoagulant activity and thrombin generation via
phosphatidylserine exposure26.
However, in the perturbed vessel wall, platelets will be in
contact with many other adhesive ligands than only collagen and
vWF. Platelets indeed express adhesive receptors for a large
number of vascular and plasma proteins2. So far, adhesion of
platelets under ﬂow conditions has been studied on surfaces
coated with ﬁbrinogen27, ﬁbronectin28, vitronectin29,30,
osteopontin, laminin31,32 and thrombospondin-1 (ref. 33).
Another relevant receptor is the C-type lectin-like receptor
(CLEC-2), which still lacks a clear physiological ligand, but yet
supports in murine studies thrombus formation in a similar way
to the collagen receptor, GPVI34–36. Precisely how these adhesive
proteins and receptors support thrombus formation under ﬂow
conditions in comparison with collagen and GPVI remains
poorly understood.
In this paper, we present a ﬁrst systematic study to compare
key physiological platelet-adhesive proteins for all major adhesive
receptors, alone and in combination, to support whole-blood
thrombus formation at speciﬁed wall shear rates. Based on this
inventory, we developed a multi-microspot test using nine
different surfaces, which we validated using blood samples from
patients with distinct platelet function deﬁciencies. Using systems
biology approaches, we employed the test outcomes for a model
predicting the roles of various receptors in thrombus formation at
high and low wall shear rate, and for a template determining
aberrations in this process in patients with platelet dysfunctions.
Results
Arrays of adhesive surfaces to assess thrombus formation. To
compare the roles of established platelet-adhesive receptors in
thrombus formation, we selected ligands of these receptors that
are present in either the vessel wall or platelet aggregates. In
addition, we used a number of chemically synthesized peptides
binding to the same receptors (Supplementary Table 1). In pre-
liminary experiments, we used different coating concentrations to
assure that the selected proteins and peptides: (i) remained bound
to degreased glass coverslips after repeated rinsing (Coomassie
staining), and (ii) showed optimal platelet adhesion under static
conditions (S.M.d.W., personal communication). Optimized sur-
faces for platelet adhesion consisted of the following proteins:
collagens I and III, decorin, ﬁbrinogen, ﬁbronectin, laminin 511/
521, osteopontin, thrombospondin-1, vitronectin and/or vWF
(Fig. 1). Also included were the snake venom rhodocytin, four
collagen-mimetic triple-helical peptides, that is, GFOGER-(GPP)n,
GFOGER-(GPO)n, (GPO)n and a vWF-binding peptide (vWF-
BP). Immobilized bovine serum albumin (BSA) served as negative
control surface. Optimally effective coating concentrations of the
collagen-mimetic peptides were established before24,37.
By coating these proteins/peptides alone or in combinations
as a row of three microspots (diameter 1,000 mm, separation
2,000 mm), and mounting the coated coverslips in a standard
parallel-plate perfusion chamber38, it was possible to determine
the thrombus-forming activity of multiple surfaces at the
same time (Fig. 2a). Tile scans performed after perfusion of
3,30dihexyloxacarbocyanine iodide (DiOC6)-labelled whole blood
indicated homogeneous adhesion of platelets to the microspots,
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either as single cells or in aggregates depending on the surface
coating (Fig. 2b). Control experiments further established that the
order of coated proteins in microspots did not affect platelet
deposition. For instance, microspotting of ﬁbrinogen, ﬁbronectin
or collagen I, at upstream or downstream positions, resulted in
the same amount of platelet adhesion and aggregation
(Supplementary Fig. 1). This pointed to the absence of
signiﬁcant paracrine cross-talk from activated platelets on
adjacent microspots.
For a comparative analysis, whole blood from healthy subjects
was perfused over microspots (three per run) containing the 52
combinations of substrate proteins and peptides at a high
(arterial) wall shear rate of 1,600 s 1. Thrombus formation on
all surfaces was measured using standardized microscopic
procedures (see Methods). Stable platelet adhesion of DiOC6-
labelled platelets was evaluated from sequential ﬂuorescence
images captured in real time during blood ﬂow. Thrombus
volume was assessed from z-stacks of confocal images of DiOC6
ﬂuorescence at end stage. End stage, phase-contrast images were
captured to determine overall platelet deposition (surface area
coverage) and platelet aggregate size. Activation of the platelets
per surface was resolved from confocal ﬂuorescence images after
labelling with ﬂuorescein isothiocyanate (FITC)-labelled anti-
ﬁbrinogen monoclonal antibody (mAb) (ﬁbrinogen binding,
integrin aIIbb3 activation), FITC-anti-CD62P mAb (P-selectin
expression) or AF647-annexin A5 (procoagulant activity). As
illustrated in Fig. 3, platelet adhesion, aggregation and activation
markedly differed between the various microspots. No platelets
adhered to spots coated with BSA (negative control), while single
platelets with low activation state adhered to coated ﬁbrinogen.
Small aggregates of platelets with activated integrin aIIbb3 and
surface-expressed P-selectin formed on coated vWF or collagen
III. Large platelet aggregates staining for all three activation
markers formed on collagen I microspots, as expected39.
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Figure 1 | Protein surfaces used for ﬂow studies and assignment map of platelet receptors interacting with indicated proteins. Assignment of
interactions of platelet receptors to immobilized protein or peptide ligands was as represented in Supplementary Table 1. Surfaces were numbered
1–52, based on unsupervised hierarchical cluster analysis of thrombus parameters (see Fig. 4). Colour code: white, not involved; black, involved at low/high
wall shear rate.
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Figure 2 | Measurement of thrombus formation on microspot arrays of
platelet-adhesive surfaces. (a) Schematic drawing of the used parallel-plate
ﬂow chamber (3mm width, 50mm depth) and microspot-coated coverslip.
Note the small-angular (11) chamber inlet and outlet, preventing ﬂow
perturbations. (b) Distribution of DiOC6-labelled platelets adhered to
consecutive microspots of collagen type I, collagen type III and vWF, after
3.5-min ﬂow of blood at wall shear rate of 1,600 s 1. Given are tile scans of
ﬂuorescence images of the full microspots (bar, 100mm). Black rims are
image artifacts due to the tile scanning. Lower panels are enlarged images.
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Control experiments were performed with blocking antibodies
(all at 20mgml 1) to verify the involvement of speciﬁc receptors
(Supplementary Table 1) to the ﬂow-dependent deposition of
platelets on microspots with single or double coatings (S.M.d.W.,
personal communication). These antibody experiments afﬁrmed
the previously established roles of: GPVI and a2b1 in thrombus
formation on collagen I or III (10B12 Ab against GPVI22,24 and
mAb 15D7 against integrin a2b1 (ref. 24)); and GPIb-V-IX for
surfaces with vWF or vWF-BP (Fab 6B4 against GPIba24). The
blocking mAb 15D7 had a moderate reducing effect on platelet
deposition on surfaces with expected contribution of a2b1 (vWF/
GFOGER-(GPP)n, vWF/GFOGER-(GPO)n), that is,  42 and
 28%, respectively (n¼ 3, Po0.05). Blocking experiments with
the anti-CD36 antibody Fab-152 gave a reduced platelet response
to thrombospondin-1 (n¼ 3, Po0.05), but unchanged platelet
deposition to vWF/thrombospondin-1. Other blocking
experiments were performed using mAb-1976 against integrin
avb3 and mAb-1969 against integrin a5b1 (20 mgml 1). Single
avb3-binding (vitronectin, osteopontin) and a5b1-binding
(ﬁbronectin) surfaces did not show platelet adhesion at high
shear rate, either in the presence or absence of the corresponding
blocking antibody. In the presence of vWF, the antibodies caused
a small but insigniﬁcant inhibition of platelet adhesion (n¼ 3,
P40.06). Based on published analyses22,24,37, an assignment
matrix was constructed of the contribution of individual adhesive
receptors to platelet interaction with the different surfaces
(Fig. 1). Herein, the well-known vWF-capturing ability of
collagens I and III was taken into account.
Identiﬁcation of thrombus type by multi-parameter analysis.
Replicate measurements of blood perfusion experiments
over all 52 coated microspots and using different ﬂuorescent
labels (nZ4 donors per condition and label) resulted in detailed
insight into the contribution of each surface to thrombus for-
mation (see wall chart in Supplementary Fig. 2). Standardized
analysis of microscopic (ﬂuorescence) images provided the
following parameters of thrombus formation: morphological
score, integrated feature size, stable platelet adhesion, ﬁbrinogen
binding, P-selectin expression, overall platelet deposition,
thrombus volume and procoagulant activity. Unsupervised
hierarchical cluster analysis of all data (52 microspots, 8 para-
meters) revealed separation into three patterns of thrombus
formation, indicated as types I–III (Fig. 4a). Surfaces producing
type I thrombi consisted of single-protein coatings causing
limited adhesion of few platelets. Type II thrombi mostly formed
on surfaces co-coated with vWF or vWF-BP causing deposition of
multiple platelets, single or in small aggregates, and showing
limited activation (ﬁbrinogen binding, P-selectin expression).
Type III thrombi formed on several combined surfaces giving
rise to large aggregates of platelets, high in activation markers.
With the exception of collagen I (which binds vWF from plasma),
Co
lla
ge
n 
I (5
1)
Brightfield
PhC
FITC-α-
CD62P
mAb
AF647
annexin A5
FITC-α-
fibrinogen
mAb 
Fi
br
in
og
en
 (1
4)
Co
lla
ge
n 
III
 (2
4)
Z-stack(DiOC6)
BS
A 
(3)
vW
F 
(28
)
x
z
y
Figure 3 | Different types of thrombi formed on various microspots. Blood from control subjects was perfused over microspots with indicated coating for
3.5min at 1,600 s 1. Shown are representative microscopic images (45 donors), from left to right: phase-contrast images of adhered platelets (i);
ﬂuorescence images of platelets binding FITC-labelled anti-ﬁbrinogen mAb (ii), FITC-labelled anti-CD62P mAb (iii) or AF647-annexin A5 (iv); further,
z-stacks from aggregates of DiOC6-labelled platelets (v). Bar, 10mm. Images from typical surfaces are given (for all 52 surfaces, see Supplementary Fig. 1).
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type III thrombi only appeared at double- or triple-coated
surfaces containing vWF, vWF-BP and/or laminin combined with
rhodocytin or (GPO)n peptides. Robustness of the unsupervised
cluster analysis was checked by data re-sampling and rebuilding
the tree by 10,000 randomizations with an approximately
unbiased P-value of 90, indicative of a strong ﬁt (Fig. 4b).
The eight output measurements clustered into adhesion-related
parameters (morphological score, integrated feature size, stable
platelet adhesion) on the one hand, and activation-related
parameters on the other hand. Cohesion of the parameters was
conﬁrmed by multiple regression analysis (Table 1), indicating
that all eight parameters contributed signiﬁcantly to the clustering
into type I–III thrombi (Po0.001). The strongest coefﬁcients of
determination for thrombus type were the linked parameters,
morphological score and integrated feature size; the linked
parameters, ﬁbrinogen binding, P-selectin expression and platelet
deposition; and procoagulant activity. Individually, two para-
meters, stable platelet adhesion and thrombus volume, were still
signiﬁcantly but less strongly determinative (R2¼ 0.71 0.68).
Complete linkage analysis after removal of the latter two
parameters resulted in a cluster plot showing the same division
into type I–III thrombi (Supplementary Fig. 3A,B). Overall, this
analysis indicates that the distinction into three types of thrombi
is not dependent on the speciﬁc measurement parameters.
However, a further division into subtypes would be parameter
dependent.
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Figure 4 | Clustering of thrombus formation at 52 microspots using eight outcome parameters. Whole blood from control subjects was perfused
over arrays of microspots in a parallel-plate ﬂow chamber for 3.5min at 1,600 s 1. Numbering of coatings with different adhesive proteins or peptides as in
Fig. 1. Recorded phase-contrast images were analysed for morphological score, integrated feature size and platelet deposition (surface area coverage).
Following in situ DiOC6 labelling, ﬂuorescence images were recorded to assess stable platelet adhesion (during blood ﬂow) and thrombus volume
(after blood ﬂow). Thrombi were poststained to determine ﬁbrinogen binding (FITC-labelled anti-ﬁbrinogen mAb), P-selectin expression (FITC-anti-CD62P
mAb), and procoagulant activity (AF647-annexin A5). Mean values of the parameters (n¼ 5–7, thrombus size: n¼4–6) were normalized from 0–10,
and arranged by unsupervised hierarchical cluster analysis. (a) Clustered heatmap for 52 different surfaces (columns) and eight measurement
parameters (rows). Clustering of surfaces revealed three different types of thrombus formation, (b) Robustness of data set, assessed by bootstrapping
randomizations of all data with Pvclust. Shown are the pro forma clusters obtained, using approximately unbiased (AU) P-values of 90 and 95,
indicative for a strong ﬁt.
Table 1 | Multiple regression analysis of measurement
parameters for the assessment of type I–III thrombi.
Parameter R 2 P R 2 P
Morphological score 0.92 (0.68) <0.001
Integrated feature size 0.91 (0.73) <0.001 0.94 <0.001
Stable platelet adhesion 0.71 <0.001
Fibrinogen binding 0.73 (0.67) <0.001
P-selectin expression 0.95 (0.68) <0.001 0.72 <0.001
Platelet deposition 0.85 (0.75) <0.001
Thrombus volume 0.68 <0.001
Procoagulant activity 0.79 (0.42) <0.001 0.69 <0.001
Given are R2 values (Pearson correlation coefﬁcient) with statistical signiﬁcance for the
contribution of each measurement parameter to the type of thrombus formation at shear rate of
1,600 s 1 for 52 surfaces (150 s 1 for 36 surfaces).
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Contributions of vWF and shear rate to thrombus type. Given
the established role of vWF/GPIb in platelet adhesion at high-
shear blood ﬂow2,21, we performed a sub-analysis of thrombi
formed on microspots co-coated with indirectly or directly GPIb-
binding substances, that is, vWF-BP or vWF, respectively. The
resulting heatmaps of Fig. 5a show that, for the majority of
microspots, the presence of vWF-BP or vWF increased thrombus
formation, as assessed from the morphological score, integrated
feature size, stable platelet adhesion, platelet deposition and
thrombus volume. Values of these parameters signiﬁcantly
increased (Po0.05, Student’s t-test) compared with the surfaces
without vWF (-BP), with the exception of microspots containing
a6b1 ligand, laminin (Fig. 5b). Other parameters, such as
ﬁbrinogen binding and P-selectin expression, increased to a
lesser extent, still signiﬁcant with co-coated vWF but not vWF-
BP. Procoagulant activity was not increased. Overall, the analysis
identiﬁed most prominent roles of vWF (-BP) on thrombus
formation co-coated with, in decreasing order, (assigned
receptors in brackets): rhodocytin (CLEC-2)4(GPO)n (GPVI),
GFOGER-(GPP)n (a2b1)4decorin, osteopontin, ﬁbrinogen,
ﬁbronectin, vitronectin (integrins a2b1, a5b1, aIIbb3, avb3)4
laminin, thrombospondin-1 (a6b1, CD36).
To substantiate this further, we also investigated the role of
vWF by comparing thrombus formation at high (1,600 s 1) and
low (150 s 1) wall shear rates, using 36 surfaces. At low shear
rate, all six parameters analysed contributed to formation of type
I–III thrombi with high coefﬁcients of determination (Table 1).
Heatmaps indicated that, in general, many surfaces that actively
supported thrombus formation at high wall shear rate performed
less well at low wall shear rate (Fig. 6a,b). On the other hand,
several of the surfaces that were less active at high shear rate,
particularly those not containing vWF, became more active at
lower shear rate. These effects were even more apparent after
subtraction analysis (Fig. 6c), pointing to improved thrombus
formation at high shear rate for all vWF-containing surfaces
(Po0.05) on the one hand. Interestingly on the other hand,
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Figure 5 | Stimulating effect of co-coating of microspots with vWF-BP or vWF. Whole blood from control subjects was perfused over arrays of
microspots for 3.5min at 1.600 s 1, and analysed for thrombus formation as in Fig. 1. (a) Sub-heatmaps of thrombus formation parameters of single
coatings (left panel), co-coatings with vWF-BP (middle panel) or co-coatings with vWF (right panel). Formation of type I, II and III thrombi is represented
by colour bars from grey to black. (b) Subtraction heatmaps, indicating the effects of co-coating with vWF-BP (middle) or with vWF (right). Colour
code is from  1 to 10. *Po0.05 (two-tailed Student’s t-test) compared with single coating, per row or column.
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combinations of laminin (a6b1), rhodocytin (CLEC-2) and
GFOGER-(GPO)n (GPVI, a2b1) provoked high and often
increased thrombus formation in the absence of vWF at lower
shear rate. Conﬁrmation of these shear-dependent effects was
obtained by perfusion studies with 19 surfaces at three wall shear
rates of 150, 1,000 and 1,600 s 1. In general, platelet deposition
at 1,000 s 1 was somewhat lower than at 1,600 s 1, the
exception being laminin-containing surfaces where highest values
were obtained at 1,000 s 1 (Supplementary Fig. 4).
Receptor combinations in type of thrombus formation. A
partial least-squares regression model was built in Matlab using
all output parameters to verify the division of thrombi into three
types, determined by unsupervised cluster analysis (Fig. 4). In the
ﬁrst model obtained, it was found that two components deter-
mined most of the variation (82.9 and 7.9%) in the data set
assessing type I, II and III thrombi; furthermore, the six key
parameters contributed similarly to this division. This allowed
us to calculate mean values of these parameters as a proxy for
the type of thrombi formed per surface and wall shear rate
(Supplementary Table 2).
A second model was then built, again using partial least-
squares regression data analysis, by ﬁtting in the data obtained at
low shear rate (which were not used in the ﬁrst model). This
model made it also possible to predict the thrombus type under
low-shear conditions (Supplementary Table 2). From this analysis
it appeared that 6 out of 11 surfaces, which each produced type I
thrombi at high shear, formed type II thrombi at low shear.
Furthermore, two out of eight vWF-containing surfaces
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Figure 6 | Effect of wall shear rate on thrombus formation on microspot surfaces. Whole blood was perfused over surfaces with or without vWF at
indicated wall shear rates. (a) Measured parameters of thrombus formation at 1,600 s 1 (2 18 surfaces, clustering order as in Fig. 4). (b) Measurement
parameters of thrombus formation at 150 s 1. (c) Linear subtraction heatmap of outcome parameters at low shear rate compared with high
shear rate. Po0.01 (two-tailed Student’s t-test).
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producing type III thrombi at high shear formed type II thrombi
under low-shear conditions. This class analysis conﬁrmed the
heatmap subtraction analysis of Fig. 6c.
By combining the analysis of thrombus types and the receptor
assignment matrix per surface (Fig. 1), we then evaluated the
combinations of receptors contributing to formation of type III
thrombi. First, computational analysis was performed for the
high-shear condition of the surfaces binding GPIb (vWF, vWF-
BP) in combination with the key integrins a2b1/a6b1 and the
signalling receptors GPVI/CLEC-2. In combination, these three
receptor/ligand classes consistently produced type III thrombi
(Fig. 7). Integrins seemed to have a stimulatory but not essential
role, with a6b1 being more active than a2b1. This was also clear
from the mean scores of laminin-containing surfaces (a6b1
binding), which performed better than GFOGER- or decorin-
containing surfaces (a2b1 binding) (Supplementary Table 2).
A similar analysis was performed by partial least-squares
regression analysis linking the various receptors to thrombus type
(high shear rate). For the 52 surfaces of the main heatmap, a new
model was built with three components (together 72% of the
variance), which after rounding gave three predicted thrombus
types. A confusion matrix indicated that only 10 of the 52
samples appeared in the wrong class, with misassignment
predominantly (8 out of 10) in the lower classes of thrombi
(type I–II), where severity was overestimated. This model was
conﬁrmed by cross validation. Using the receptor assignments per
surface, a b-weight matrix was constructed to calculate the
contribution of each receptor to the type of thrombus formation
(Table 2). The matrix conﬁrmed prominent differences in
contribution of the various receptors, pointing to major roles
for GPIb, the signalling receptors GPVI and CLEC-2, as well as
for the integrins a6b1 and aIIbb3. While contribution of a2b1 is
less pronounced, the other integrins a5b1 and avb3 along with
CD36 score lowest. Note that negative values in the matrix only
indicate relative inability of the receptor to contribute to type III
thrombus formation. Overall, these ﬁndings identify highly
stimulatory roles of CLEC-2 and a6b1 in type III thrombus
formation at high shear rate, in addition to the established roles of
GPIb, GPVI and a2b1.
Using the same receptor assignments and partial least-squares
regression analysis, a new b-matrix was built to predict the
contributions of individual receptors at low shear rate, that is, by
clustering the low-shear data into the matrix of high-shear data.
Cross-validation predictions showed that only 7 of the 36 surfaces
were wrongly predicted for thrombus type. The resulting
b-weight factors (two components, 58% of the variance) pointed
to a minimized contribution of GPIb to thrombus type at low
shear rate (Table 2). Further, this analysis indicated similarly high
contributions of GPVI, CLEC-2, a6b1 and aIIbb3. At low shear
rate, CD36 had a positive role, while avb3 and a5b1 again did not
contribute to formation of type III thrombi. Finally, the model
was rebuilt by exclusion of a contribution of GPIb at low shear
rate, giving essentially the same results (only 4 out of 36 surfaces
wrongly predicted). This calculated absence of the GPIb-V-IX
at low-shear ﬂow conditions is in good agreement with the
literature2.
Platelet function disorders leading to impaired thrombus for-
mation. A panel of nine microspot surfaces (all major receptors
and vWF co-coated) was selected to determine reference values of
all parameters for nZ6 healthy subjects (Supplementary Table 3).
To assess intra-individual variability, blood samples were ana-
lysed from six healthy volunteers, taken each at four different
days. For all surfaces together: intra-individual coefﬁcient of
variations (CVs) for the morphological score (5.7%) were 2.0
times lower than inter-individual CVs (11.2%); for platelet
deposition, intra-individual CVs (10.8%) were 3.1 times lower
than inter-individual CVs (33.7%). Similarly, for the platelet
activation markers, that is, ﬁbrinogen binding, P-selectin
expression and phosphatidylserine (PS) exposure, intra-indivi-
dual CVs were 3.4 times, 2.6 times and 3.5 times lower, respec-
tively, than the corresponding inter-individual CVs.
Thrombus formation was also assessed in blood from rare
patients with established platelet function disorders. Heatmap
mean data were generated for the control subjects and the
individual patients under investigation (Fig. 8a,b). These data
were further evaluated in subtraction heatmaps and signiﬁcance
maps (Fig. 8c,d).
Thrombus formation was assessed in blood from a patient with
severe immune deﬁciency syndrome (SCID)40, associated
with near-complete deﬁciency in store-induced calcium entry in
haematopoietic cells including platelets. In spite of a reduced
morphological score of thrombus formation, platelet activation
parameters on surfaces producing type III thrombi, that is, vWF/
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Figure 7 | Contribution of platelet-adhesive receptors to formation of type I–III thrombi. Schematic representation of thrombus type formed at
high shear rate on surfaces capturing platelets via adhesive receptors (GPIb, and integrins a2b1, a6b1) as well as signalling-linked receptors (GPVI, CLEC-2).
Table 2 | Predicted contribution of platelet receptors in
formation of type III thrombi at high shear rate.
Receptor Weight factor 1,600s 1 150 s 1
b constant 0.947
GPIb-V-IX 0.687 0.049
GPVI 0.858 0.903
CLEC-2 0.763 0.964
a6b1 0.653 0.879
aIIbb3 0.527 0.877
a2b1 0.193 0.165
CD36 0.262 0.898
a5b1 0.102 0.834
avb3 0.159 0.746
Beta matrix values after principal component analysis of weight factors, predicting the
contribution of individual adhesive receptors to formation of type III thrombi. The model built for
shear rate of 1,600 s 1 was based on 52 surfaces and six parameters (71% of variance). A
separate-scaled model was built for shear rate of 150 s 1, based on 36 surfaces and six
parameters (58% of variance). Both models used the assignment matrix of Fig. 1. Note that
negative values designate relative inactivity of the receptors to participate in type III thrombus
formation.
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Figure 8 | Abnormal thrombus formation in blood from patients with rare platelet function defects. Whole blood from controls subjects or indicated
patients was perfused over microspots of nine different surfaces (three microspots per run, 2–3 runs per surface). Surface numbering as in Fig. 1.
(a) Heatmap of average parameters of thrombus formation for blood samples from control subjects (left), and blood samples from day control subjects
(right). (b) Heatmaps and (c) subtraction heatmaps of parameters of thrombus formation for patients with indicated syndromes: SCID, May–Hegglin
anomaly, grey platelet syndrome, Glanzmann’s thrombasthenia or Hermansky–Pudlak syndrome. *Po0.05 compared with control subjects (two-tailed
Student’s t-test). (d) Signiﬁcance map of parameters from a representative control subject and a day control subject, as well as from all patients.
Colour key: red¼ deviating omean 2 s.d.; green¼ deviating 4meanþ 2 s.d., relative to normal values.
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rhodocytin and collagen I, were increased in comparison with
control subjects (Fig. 8d,e). This may point to increased CLEC-2-
and GPVI-dependent platelet activation under high shear ﬂow,
for example, compensating for the absence of one of the calcium
entry pathways. Blood samples were also examined from a patient
with May–Hegglin anomaly41, characterized by a myosin
cytoskeletal defect and macrothrombocytopenia, in which
disease the consequences for platelet function are not well
understood. Thrombus formation parameters were mostly within
the normal range, with the exception of reduced platelet aggregate
formation (morphological score, integrated feature size, platelet
deposition) on GPVI-binding surfaces (vWF, vWF/GFOGER-
(GPO)n, collagen I). Most values for nonGPVI-binding surfaces
were in the normal range. However, platelet procoagulant activity
tended to be higher on two-component surfaces.
Also investigated was blood from a patient with grey platelet
syndrome41, phenotyped with a partial deﬁciency in platelet a-
granules. The thrombi formed were reduced in most parameters,
with the exception of procoagulant activity, typically on type III-
inducing surfaces, that is, vWF/rhodocytin, vWF/GFOGER-
(GPO)n and collagen I (Fig. 8d). P-selectin expression was
markedly reduced on all surfaces, as expected. Overall, these
results may point to impaired thrombus formation due to the
reduced a-granule release, in particular on surfaces activating via
CLEC-2 or GPVI. Furthermore, testing the blood from a patient
with Glanzmann’s thrombasthenia (deﬁciency in aIIbb3) resulted
in a signiﬁcant reduction in platelet aggregation tendency
(morphological score, integrated feature size and/or ﬁbrinogen
binding) on most surfaces, thus substantiating aIIbb3 as being
invariably implicated in platelet–platelet interactions. Platelet
activation parameters (P-selectin expression, platelet deposition)
were most prominently reduced on vWF/ﬁbrinogen surface. A
ﬁnal blood sample was used from a patient with Hermansky–
Pudlak syndrome41, characterized by absence of dense granules.
In this case, parameters of thrombus formation decreased with
vWF/vitronectin, vWF/rhodocytin, vWF/GFOGER-(GPO)n and
collagen I. Thrombus formation hence diminished on surfaces
binding GPIb plus avb3, CLEC-2 or GPVI. For all patients
together, thrombus formation was mostly altered on vWF-
containing surfaces with rhodocytin, GFOGER-(GPO)n or
collagen-I; the most affected parameters were morphological
score, integrated feature size and ﬁbrinogen binding.
Additional role of thrombin. To determine the role of thrombin,
as a potent platelet agonist in thrombus formation, recalciﬁed
blood samples were ﬂowed over microspots containing surfaces
co-coated with tissue factor. Corn trypsin inhibitor and Gly-Pro-
Arg-Pro were added to prevent contact activation and ﬁbrin
polymerization, respectively. Representative results are given in
Supplementary Table 4. On a vWF/ﬁbronectin surface, all para-
meters of thrombus formation increased in the presence of
thrombin generation. However, on coated collagen-I, platelet
deposition and ﬂuorescence markers of platelet activation para-
meters appeared to decrease in the presence of thrombin. This
paradoxical effect was due to contraction of the thrombi on
collagen, resulting in lower surface area coverage of the (labelled)
platelets in the presence of thrombin. Incidental presence of ﬁbrin
clots on the surfaces made this assay variant less suitable for
standardization. Overall, these data pointed to a more complex
way of thrombus phenotyping in the presence of thrombin, which
requires further evaluation in the future.
Discussion
The present results aim to contribute to the recognized high need
for full standardization and exploitation of ﬂow assays for
integrative whole-blood platelet function testing9. By systematic
assessment of thrombus formation under high shear ﬂow on
52 microspot surfaces using eight outcome parameters, we have
identiﬁed the most determinative parameters of this process.
These reﬂect overall platelet adhesion and aggregation
(morphological score, integrated feature size, platelet
deposition), and determinants of platelet activation (ﬁbrinogen
binding, P-selectin expression, procoagulant activity). Leaving out
two parameters—stable platelet adhesion and thrombus
volume—did not change the initial clustering of surfaces with
different types of thrombi. The remaining six parameters
contributed equally to the thrombus-forming process, and were
hence combined in least-squares regression analyses to build a
model for the formation of thrombi with different phenotypes.
The division into three thrombus types was almost identical to
that achieved by unsupervised cluster analysis of all data (52
surfaces, 8 parameters).
The cluster analysis indicated a robust distinction of surfaces
into three classes, supporting: adhesion of few single platelets
(type I); extensive adhesion with small aggregates and minimal
platelet activation (type II); or large aggregates with fully activated
platelets (type III). Thrombi of type III were only present on
combined microspots containing vWF or vWF-BP, an exception
being collagen I which binds vWF from plasma; other necessary
components were laminin (binding a6b1), peptides containing
(GPO)n (binding GPVI) or rhodocytin (binding CLEC-2). Other
adhesive proteins tested appeared to be less active in combined
surfaces (ﬁbrinogen4osteopontin, collagen III4ﬁbronectin,
vitronectin, thrombospondin-1, decorin). Note that the CLEC-2
ligand podoplanin is not present in the arterial wall or in
plasma35.
A particular role in high-shear thrombus formation is played
by vWF, because it binds to two abundant platelet receptors,
GPIb and aIIbb3 and to several matrix proteins2, that is, ﬁbrillar
collagens (via its A3 domain)19 and, as recently demonstrated, to
laminins42. The latter ﬁnding explains why we could not identify
co-operative roles of vWF and laminin on microspots and high
activity of laminin/rhodocytin co-coatings. For the majority of
other surfaces, co-coating of vWF (or vWF-BP) increased the
parameters of thrombus formation at high shear rate, but not at
low shear rate. The platelet-activating effect of surface-
immobilized laminin has been observed before under stasis, and
was attributed to a6b1 and GPVI32,43. However, using GPVI
inhibitors we did not ﬁnd a role of GPVI in ﬂow-dependent
platelet adhesion and activation on laminin. Our data with
microspotted peptides agree with the earlier conclusion that
synthetic peptides designed to mimic platelet-collagen
interactions via GPVI, vWF/GPIb and a2b1, namely (GPO)n,
vWF-BP and GFOGER peptides, can completely replace native
collagen ﬁbres in supporting thrombus formation24,37,44.
Regression models built to predict the involvement of different
platelet receptors to full-thrombus formation yielded interesting
results. In addition to the established contribution of GPIb and
GPVI, we ﬁnd major roles for CLEC-2 and the integrins a6b1 and
aIIbb3. At high shear rate, platelet adhesion via integrin a2b1
contributed little to type III thrombus formation, while other
receptors avb3, a5b1 or CD36 were even less effective. This
conclusion is in full accordance with the major and additive roles
of GPVI, CLEC-2 and integrin a6b1 in arterial thrombus
formation in established mouse models of arterial thrombus
formation in vivo35,42. Importantly, ﬁtting the low-shear data into
these regression models pointed to an almost annulled
contribution of GPIb, which is in accordance with the current
concept of the GPIb-V-IX complex as key receptor for platelet
adhesion at high-shear conditions2. Although these results
indicate a strong role of this complex in the formation of type
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III thrombi at high shear, they do not prove that GPIb itself
triggers signalling events in platelets. According to the built
model, the other most remarkable change in weight factors at low
shear rate is a positive contribution of CD36.
Normal values were determined for nine surfaces and six
outcome parameters. In particular, the parameters ﬁbrinogen
binding, P-selectin expression, platelet deposition and platelet
procoagulant activity showed high inter-sample variation. High
inter-individual variability in platelet deposition on collagen
surfaces has also been reported by others, and could be correlated
to plasma levels of vWF, platelet count, haematocrit, sex and
platelet receptor genotype14. Using different types of microﬂuidic
devices, it has also been possible to correlate outcome parameters
of thrombus formation to platelet calcium responses (under
stasis)15, and to aspirin and/or clopidogrel intake in patients with
heart disease16. Taken together, the inter-individual variability in
this kind of whole-blood measurements seems to be linked, at
least in part, to clinically relevant determinants of platelet
function in cardiovascular disease.
Consistent results were obtained upon application of the multi-
parameter microspot assay to blood from patients with
established platelet deﬁciencies in platelet functions. With the
exception of blood from the SCID patient, the overall effect of
disease on all parameters was reduced thrombus formation (9–18
out of 54 parameters reduced) (Fig. 8d). Spots of collagen I, vWF/
GFOGER-(GPO)n and vWF/rhodocytin were most discrimina-
tive, all normally resulting in type III thrombi. Of the type II
thrombus-inducing surfaces, only vWF/vitronectin showed two
reduced parameters for the majority of patients. Together, the
patient data indicate that this multi-parameter, multi-surface test
detects the consequences of actin cytoskeleton alterations (May–
Hegglin), deﬁcient alpha or dense granule secretion (grey platelet,
Hermansky–Pudlak) and impaired aIIbb3 activity (Glanzmann).
However, in the case of impaired store-operated calcium entry
(SCID patient), we ﬁnd a similar number of parameters decreased
and increased.
In conclusion, we developed a standardized procedure to
systematically test thrombus formation upon whole-blood
perfusion over arrays of microspotted adhesive surface. Using
systems biology approaches, we built a model predicting the roles
of platelet receptors in shear-dependent thrombus formation, and
generated templates to determine aberrations in this process in
patients with platelet dysfunctions. This knowledge of surfaces
and output parameters is pivotal in the planned design of
microscope-independent ﬂow devices. Applications of this
advanced technique are numerous, not only in the proﬁling of
patients with a (suspected) bleeding disorder or a pro-thrombotic
tendency, but also in the monitoring of functional aberrations in
platelet count and of antiplatelet therapy. Furthermore, in a
modiﬁed way, it can be used to assess the platelet-adhesive
properties under ﬂow of blood-derived leukocytes, natural stem
cells and malignant cells in cancer.
Methods
Materials. Sources of proteins for microspot coatings are indicated in
Supplementary Table 5. VWF puriﬁed from human plasma was obtained from
University Medical Center Utrecht45. Rhodocytin was puriﬁed by gel ﬁltration
and ion-exchange chromatography from venom of the Malayan pit viper,
Calloselasma rhodostoma46. The following triple-helical peptides were synthesized
as C-terminal amides and were puriﬁed by reverse-phase high-performance
liquid chromatography47: H-GPC(GPO)3GFOGERGPO)3GPC-NH2 [GFOGER-
(GPO)n]; H-GPC(GPP)5GFOGER(GPP)5GPC-NH2 [GFOGER-(GPP)n] and cross-
linked collagen-related peptide, (GPO)n (ref. 48); H-GPC(GPP)5GPRGQOGV
MGFO(GPP)5GPC-NH2, collagen type III derived vWF-BP, also called VWF-III
(ref. 44). BSA was obtained from Sigma; D-phenylalanyl-L-prolyl-L-arginine
chloromethylketone (PPACK) from Calbiochem; DiOC6 from AnaSpec; corn
trypsin inhibitor from Haematologic Technology; recombinant human tissue factor
from Dade-Behring; Gly-Pro-Arg-Pro from Stago.
Anti-ﬁbrinogen antibody labelled with FITC was from WAK Chemie; FITC-
labelled anti-CD62P (P-selectin) mAb from Immunotech; annexin A5 labelled with
Alexa ﬂuor (AF)647 from Molecular Probes. Blocking mAbs against speciﬁc
receptors came from the following sources: mAb-1950 against integrin a2, mAb-
1976 against integrin avb3 and mAb-1969 against a5b1 from Merck-Millipore; Fab-
152 against CD36 from Santa Cruz; chimeric mAb abciximab, directed against
integrins aIIbb3 and avb3 from Centocor. Sources of single-chain Ab 10B12 against
GPVI48, mAb 15D7 against integrin a2b1 (ref. 48) and of 6B4 Fab2 fragment
against the vWF-binding site on GPIba49.
Microspotting of proteins and peptides. Glass coverslips (24 60mm, Menzel)
were degreased with 2M HCl in 50% ethanol, and rinsed with water and saline.
Using a precision mall, arrays of three consecutive microspots (3mm centre-to-
centre distance) were applied on coverslips as 0.5 ml volumes of coating proteins or
peptides. Coating concentrations were optimized to give maximal static platelet
adhesion, previously established in the range of 50–250 mgml 1 (refs 24,37,45).
Osteopontin, vitronectin and vWF were applied at 50 mgml 1; collagens, vWF-BP,
laminin and thrombospondin-1 at 100mgml 1; and other proteins and collagen-
related peptides at 250 mgml 1. Coated podoplanin did not support platelet
adhesion, and was not used for further experiments. Sources of coated proteins and
peptides are given in Supplementary Table 5. Microspots with double or triple
coatings were prepared by mixing the desired proteins or peptides at the con-
centrations above.
Microspot-coated coverslips were incubated for 1 h in a humid atmosphere, and
washed twice with saline. Coatings were veriﬁed by staining with Coomassie
brilliant blue G, showing circular stained spots ofB1,000 mm in diameter for most
coated proteins; only laminin and collagen I gave smaller (800 mm) and larger
(1,200 mm) spots, respectively. Before ﬂow perfusion, coverslips were blocked with
HEPES buffer pH 7.45 (136mM NaCl, 10mM HEPES, 2.7mM KCl, 2mM MgCl2,
0.1% glucose, 1 Uml 1 heparin) supplemented with 1% BSA.
Healthy control subjects and patients. Studies were approved by the local
Medical Ethics Committee (Maastricht University Medical Centre,
NL31480.068.10). Blood samples (10ml) were taken from healthy control subjects
and patients, who had not used antiplatelet or anti-inﬂammatory medication for 2
weeks. All donors gave informed consent in accordance to the Declaration of
Helsinki. Healthy controls (both sexes, age 23–58 years) were not under medical
care, had not experienced bleeding problems, and had normal platelet counts (200–
300 109 l 1) and haematocrit values (32–42%). For determination of intra-
subject variability, blood samples from six healthy donors were taken on four
different days, perfused and analysed.
Patients all had a well-deﬁned platelet deﬁciency and mild bleeding tendency, as
reported by the examining physicians: a patient with Glanzmann’s thrombasthenia
with conﬁrmed deﬁciency in platelet aIIbb3 expression and normal blood cell
counts50; a patient with SCID, ORAI1 mutation and abolished store-regulated
inﬂux in platelets51; a patient with May–Hegglin anomaly (MYH9 gene mutation)
displaying macrothrombocytopenia (9 109 platelets l 1) and a relatively high
haematocrit level (46%); a patient with conﬁrmed Hermansky–Pudlak syndrome
(HPS3 gene mutation), characteristically lacking platelet dense granules, as
conﬁrmed by ﬂow cytometry (280 109 platelets l 1, haematocrit 31%); a patient
with suspected grey platelet syndrome with major deﬁciency in platelet a-granules
and reduced P-selectin expression, which was accompanied by macrothrombo-
cytopenia (37 109 platelets l 1, haematocrit 33%). Blood samples from every
patient were run in parallel to blood samples from healthy travel controls.
Blood collection. Blood collection was into 0.1 volume of saline containing
PPACK (40 mM) and fragmin (40Uml 1, ﬁnal concentrations); alternatively,
where indicated, collection was into 0.1 volume of sterile 129mM trisodium citrate.
Citrated blood samples were recalciﬁed with 3.75mM MgCl2 and 7.5mM CaCl2
(ﬁnal concentrations) in the presence of PPACK (40 mM) and fragmin (40Uml 1)
prior to the ﬂow experiment. Prior to perfusion, blood samples were checked for
platelet counts and the absence of visible clots.
Flow chamber device and ﬂow perfusion protocol. Microspot-coated coverslips
were mounted onto a transparent parallel-plate ﬂow chamber (50 mm depth, 3mm
width and 20mm length), and pre-rinsed with HEPES buffer pH 7.45 containing
0.1% BSA. Anticoagulated whole-blood samples (400–500 ml) were perfused
through the ﬂow chamber for a time period sufﬁcient for full-thrombus formation
on collagen I spots, that is, 6min at 150 s 1, 4min at 1,000 s 1 and 3.5min at
1,600 s 1. Where indicated, blood samples were preincubated for 5min with
DiOC6 (0.5mgml 1), and ﬂuorescence images were recorded from the microspots
during blood perfusion. In other cases, thrombi formed after blood ﬂow were
poststained by 2-min perfusion (1,000 s 1) with colour-selected combinations of
the following platelet activation markers: FITC-labelled anti-ﬁbrinogen mAb
(1:100), FITC-labelled anti-P-selectin mAb (1.25 mgml 1) and/or AF647-annexin
A5 (0.25 mgml 1), all in HEPES buffer pH 7.45 supplemented with 0.1% BSA.
After 2min of staining (stasis), unbound label was removed by a short perfusion
with the same HEPES buffer. No ﬁxative was used.
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To assess the role of thrombin on thrombus formation under high-shear ﬂow
conditions, tissue factor (500 pM) was immobilized together with a dual coating of
vWF with ﬁbronectin or collagen-I. Corn trypsin inhibitor (5 mgml 1) was present
in the blood collecting tube to inhibit the contact activation pathway of
coagulation. Blood was drawn on 0.32% trisodium citrate and Gly-Pro-Arg-Pro
(5mgml 1) was added to block ﬁbrin polymerization and thus clot formation.
During the ﬂow perfusion, the blood was recalciﬁed with 6.3mM CaCl2 and
3.2mM MgCl2 to allow thrombin to be formed via co-coated tissue factor. Platelet
activation markers were determined as described for the noncoagulating
conditions.
Standardized recording of microscopic images. Phase-contrast bright-ﬁeld
images were recorded from all three microspots during buffer perfusion immedi-
ately after outﬂow of the red blood cells, using an inverted Nikon Diaphot
microscope, equipped with a  40 oil-immersion objective (numerical aperture,
1.3), a  1.8 relay lens and a CCD camera (640 480 pixels)38. For measuring
platelet activation markers, the ﬂow chamber was placed on the stage of a confocal
Bio-Rad/Zeiss MRC-600 microscope, equipped with a  60 oil-immersion
objective (numerical aperture 1.4). Dual-colour confocal ﬂuorescence 8-bit images
(512 512 pixels) were recorded at 488 and 633 nm excitation and settings, as
described previously52. Thrombus volume was determined using a fast line-
scanning Zeiss LSM7 microscope system, equipped with a  63 oil objective.
Confocal z-stacks were recorded of DiOC6-labelled platelets in thrombi (8-bit
images of 512 512 pixels; 106 106mm, stack distance 0.5 mm). The same label
and system were used to measure stable platelet adhesion during blood ﬂow (8-bit
images, taken at 2-s intervals). For each ﬂow run, ﬁve representative microscopic
images were taken from each of the microspots. Flow assays per blood sample were
performed in duplicate or in triplicate, if duplicates showed marked variation.
Quantitative analysis of recorded images. Phase-contrast and ﬂuorescence
images were analysed by standardized journals, using Metamorph software
(Molecular Devices), or in the case of LSM7 images with Axiovision Rel.4.8 soft-
ware (Carl Zeiss). End-stage phase-contrast images of adhered platelets were
judged as follows. The morphological score was obtained by visual inspection of the
platelet features per microspot: 0, no or hardly any adhered platelets; 1, multiple
single-adhered platelets; 2, extensive coverage of single-adhered platelets; 3, small
platelet aggregates; 4, intermediate platelet aggregates; 5, full thrombi with large-
size platelet aggregates. Platelet deposition was determined as surface area coverage
by using supervised image analysis journals. In brief, auto-enhanced images were
ﬁltered vertically and horizontally and thresholds were set. The resulting binary
images were subjected to a close-and-open ﬁlter, which resulted in identiﬁed
regions of single or clustered adhered platelets. The integrated feature size was
determined as a parameter, taking into account a proportional contribution of large
and small thrombi on microspots. It was deﬁned as the cumulative contribution of
squared feature areas (f2), ranked from small to large (1N), to the total feature
size (Sf) (equation 1):
XN
i¼1
f 2i
 
=
XN
i¼1
fi ð1Þ
In cumulative plots, where larger size features appear at the right, the area above
the curve represents a value of the integrated feature size.
Time series of images of DiOC6 ﬂuorescence (1min, 2-s intervals) were
converted into subtracted, differential images using Metamorph software, and
analysed for changes in pixel intensity above background53, thus producing a value
for stable platelet adhesion. Confocal ﬂuorescence images were thresholded with
predeﬁned journals using Metamorph software, to obtain percentage values of
surface area coverage for each platelet activation label: FITC-anti-ﬁbrinogen mAb
(aIIbb3 activation), FITC-anti-P-selectin mAb (a-granule secretion; correction for
non-speciﬁc labelling), AF647-annexin A5 (phosphatidylserine exposure)38.
Z-stacks of confocal images of DiOC6 ﬂuorescence were analysed with Axiovision
software to obtain a summed thrombus volume per surface area37. Protocols were
checked by three different observers, who were blinded to the experimental
variables.
Bioinformatics and statistics. For comparative analysis, mean values of all
thrombus parameters from 52 surfaces were linearly normalized to a range from
0–10 (values of all parameters were normally distributed). Two-way unsupervised
hierarchical clustering was performed using the R package version 2.3
(www.r-project.org). Euclidean distances were calculated, and clustering was by
complete linkages. Robustness of the clusters was checked using the R program,
Pvclust. The clusters were rebuilt based on 10,000 randomizations, and their sig-
niﬁcance was assessed using an approximately unbiased P490. Pvclust was also
used to evaluate the robustness of the clusters by leaving out particular surfaces or
parameters, with the aim to select those surfaces and parameters giving non-
redundant information. Partial least-squares regression models with b-matrices
were built in Matlab, and were employed to make 2–3-component prediction
models for thrombus type and platelet receptor contribution. All models were
checked by cross-validation predictions.
Parameters were correlated or compared by multiple regression analysis using
the statistical package for social sciences (SPSS 19.0). Patient data were compared
with normal ranges established for healthy control subjects, and statistically
analysed by probability analysis. Effects of antibodies and heatmap subtractions
were compared using a two-tailed Student’s t-test.
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